Compass Capital Management Inc. Invests $55.69 Million in Boston Scientific Corporation $BSX

Compass Capital Management Inc. acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 584,068 shares of the medical equipment provider’s stock, valued at approximately $55,691,000. Boston Scientific makes up 3.1% of Compass Capital Management Inc.’s investment portfolio, making the stock its 17th largest position.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Meiji Yasuda America Inc purchased a new stake in shares of Boston Scientific in the 4th quarter worth $4,708,000. Absolute Capital Management LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth $670,000. Sumitomo Mitsui Financial Group Inc. increased its stake in shares of Boston Scientific by 1.5% in the 4th quarter. Sumitomo Mitsui Financial Group Inc. now owns 269,875 shares of the medical equipment provider’s stock worth $25,733,000 after purchasing an additional 4,094 shares in the last quarter. Xponance LLC increased its stake in shares of Boston Scientific by 6.0% in the 4th quarter. Xponance LLC now owns 262,902 shares of the medical equipment provider’s stock worth $25,068,000 after purchasing an additional 14,848 shares in the last quarter. Finally, Parnassus Investments LLC increased its stake in shares of Boston Scientific by 14.7% in the 4th quarter. Parnassus Investments LLC now owns 7,899,240 shares of the medical equipment provider’s stock worth $753,193,000 after purchasing an additional 1,014,800 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BSX shares. BTIG Research reduced their price objective on Boston Scientific from $80.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, June 2nd. Barclays reduced their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research note on Thursday, May 28th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a research note on Thursday, May 28th. Weiss Ratings lowered Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $85.92.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: BTIG reiterated a bullish view on Boston Scientific, highlighting a low forward P/E and significant upside potential, which may help support the stock after its sharp year-to-date de-rating. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Recent analyst commentary still shows broad Wall Street support, with several buy ratings and price targets well above the current trading range, suggesting some investors see the selloff as overdone.
• Neutral Sentiment: Boston Scientific’s Q1 results beat estimates slightly, with revenue up 11.6% year over year, but the market appears more focused on forward guidance and segment-level growth trends than the last quarter’s results.
• Neutral Sentiment: Erste Group trimmed FY2026 and FY2027 EPS estimates only modestly, signaling little change to the core earnings outlook, though the revisions add to the cautious tone around near-term expectations.
• Negative Sentiment: The stock has been sliding after a guidance reduction and renewed scrutiny over slower growth in important businesses, including WATCHMAN and ablation technologies, which is weighing on investor confidence. Boston Scientific Stock (BSX) Opinions on Recent Stock Decline
• Negative Sentiment: A recent market update showed BSX declined again in the latest session, reinforcing the bearish momentum that has followed the guidance-related selloff. Boston Scientific (BSX) Stock Moves -1.27%: What You Should Know

Boston Scientific Trading Down 2.3%

Shares of BSX stock opened at $47.22 on Friday. Boston Scientific Corporation has a 52-week low of $46.91 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The firm has a market capitalization of $70.18 billion, a PE ratio of 19.76, a PEG ratio of 0.91 and a beta of 0.56. The stock has a fifty day simple moving average of $56.68 and a two-hundred day simple moving average of $75.14.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the business posted $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, Director David C. Habiger acquired 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.